SABS.O (SABS.O) News
Follow SABS.O (SABS.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
SAB Biotherapeutics to join Chardan Annual Healthcare Conference fireside chat
SAB Biotherapeutics will join the Chardan 10th Annual Healthcare Conference on Oct. 20, 2026, in New York. CEO Samuel J. Reich will take part in an 11:15—11:30 a.m. ET fireside chat. Disclaimer: This news brief was creat
NEWS | Oct 14, 2026, 12:32 PM UTC
L
SAB Biotherapeutics says FDA grants Fast Track designation for SAB — 142 in stage 3 type 1 diabetes
FDA granted Fast Track designation to SAB Biotherapeutics’ SAB-142 for new-onset Stage 3 type 1 diabetes. Candidate is in the registrational Phase 2b SAFEGUARD study, with enrollment expected to finish in Q4 2026. Toplin
REGULATION | Oct 13, 2026, 12:32 PM UTC